These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16571300)

  • 1. [New types of dopaminergic treatment. The Danish Society of Movement Disorders].
    Karlsborg M; Regeur L
    Ugeskr Laeger; 2006 Mar; 168(12):1209. PubMed ID: 16571300
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effective therapy option in the late phase of Parkinson disease: subcutaneous apomorphine].
    Krankenpfl J; 2005; 43(7-10):241. PubMed ID: 16515311
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclamol and parkinsonian fluctuations.
    Pirtosek Z; Merello M; Carlsson A; Stern G
    Clin Neuropharmacol; 1993 Dec; 16(6):550-4. PubMed ID: 9377590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 7. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

  • 8. [Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
    Aschermann Z; Kovács N; Komoly S
    Ideggyogy Sz; 2013 May; 66(5-6):209-10. PubMed ID: 23909024
    [No Abstract]   [Full Text] [Related]  

  • 9. [Parkinson disease--planning of long-term therapy].
    Nervenarzt; 1997 Dec; 68(12 Suppl Morbus Par):1-8. PubMed ID: 9439751
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC; Burguera JA
    Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 13. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    Mundt-Petersen U; Odin P
    Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
    Garcia Ruiz PJ
    Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 16. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
    Stocchi F; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Apr; 20(2):95-115. PubMed ID: 9099462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.